Cédric Draulans

[Federica Ferrario @Fefe_Ferrario]

🧨 Join us for #PCa #SBRT Symposium by @StAr_MCM74 & @PanizzaDenis with 🔝tier international faculty @piet_ost @CDraulans @CZamboglou and 🌟Italian RadOncs together with @ESTRO_RT President @BarbaraJereczek

🔗Registrations open—limited seats
https://t.co/icoFJ27mw5

@valefacc22

[Cédric Draulans @CDraulans]

🙏Thank you patients and @komop_tgkanker for supporting the hypo-FLAME trial! This trial recruited n=100 across 4 sites in 🌷🇳🇱 and 🍫🇧🇪 between 2016-2018.

Iso-toxic focal boosted prostate #SBRT ➡️ 5y-bDFS = 93%, reported in @RadiotherapyOn1

Full text:
https://t.co/SODFIRXRZa

[Thomas Zilli @ZilliThomas]

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial https://t.co/9KGnZJ5QlE

[Cédric Draulans @CDraulans]

@CZamboglou @alison_tree @SprakerMDPhD @jryckman3 Fully agree, with what we know so far, an adequate GTV detection/delination and achieving the best possible minimum coverage of that GTV seem to be the two most crucial factors to get the best outcomes with focal boosting.

[Cédric Draulans @CDraulans]

@alison_tree @SprakerMDPhD @jryckman3 Indeed, Karolina Guricova showed that in the FLAME cohort the coldest spot to the GTV determines outcome when comparing near minimum dose D98% vs. median dose D50%.

https://t.co/8GEbMtwfJd